Interestingly, other studies have shown that in MPN patients with JAK2 V617F and TET2 mutations, the presence of the TET2 mutation in single cell-derived clones conferred an advantage towards clonal dominance, but not JAK2 V617F on its own (103, 104). The gene discussed is JAK2; the disease is myeloproliferative disorder.